BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 276,400 shares, an increase of 130.9% from the July 15th total of 119,700 shares. Based on an average trading volume of 331,900 shares, the days-to-cover ratio is presently 0.8 days.
BioLineRx Stock Performance
BLRX stock traded down $0.01 during midday trading on Wednesday, hitting $0.76. 78,447 shares of the stock traded hands, compared to its average volume of 365,189. BioLineRx has a 1-year low of $0.51 and a 1-year high of $2.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.14 and a quick ratio of 1.05. The stock’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.84. The firm has a market cap of $60.68 million, a P/E ratio of -0.99 and a beta of 1.52.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.28. The business had revenue of $6.86 million for the quarter, compared to analyst estimates of $0.34 million. During the same quarter last year, the business earned ($0.15) earnings per share. On average, analysts expect that BioLineRx will post -0.25 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of BioLineRx in a report on Wednesday, May 29th. StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.
Read Our Latest Research Report on BioLineRx
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than BioLineRx
- Top Stocks Investing in 5G Technology
- Brinker International’s Price Dip is an Appetizing Entry Point
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Stocks That Could Beat the September Blues
- ESG Stocks, What Investors Should Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.